Product
Surufatinib and Tislelizumab
Aliases
HMPL-012, sulfatinib, BGB-A317, Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
1 clinical trial
7 indications
Indication
Metastatic Solid TumorIndication
Colorectal CancerIndication
Neuroendocrine TumorsIndication
Small Cell Lung CancerIndication
Stomach CancerIndication
Soft Tissue SarcomaIndication
Anaplastic Thyroid CancerClinical trial
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-04-30